Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERGOLOID MESYLATES vs ERGOTAMINE TARTRATE AND CAFFEINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Ergotamine is a partial agonist/antagonist at serotonin (5-HT), dopamine, and alpha-adrenergic receptors, causing vasoconstriction of cranial blood vessels. Caffeine enhances ergotamine absorption and has additive vasoconstrictive effects.
Treatment of age-related cognitive decline,Dementia (unlabeled use)
Acute treatment of migraine headaches with or without aura,Acute treatment of cluster headaches
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
Oral: 2 mg ergotamine tartrate and 200 mg caffeine at onset of migraine, then 1 mg ergotamine tartrate and 100 mg caffeine every 30 minutes as needed; maximum 6 mg ergotamine tartrate and 600 mg caffeine per day or 10 mg ergotamine tartrate and 1000 mg caffeine per week. Rectal: 2 mg ergotamine tartrate and 200 mg caffeine as a single suppository at onset; repeat once after 1 hour if needed; maximum 4 mg ergotamine tartrate and 400 mg caffeine per day or 8 mg ergotamine tartrate and 800 mg caffeine per week.
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Ergotamine has a terminal elimination half-life of approximately 2 hours (range 1.5–2.5 hours) for the alpha phase, but a longer terminal half-life of 12–24 hours due to slow tissue release; this contributes to its prolonged duration of action and risk of accumulation with frequent dosing.
Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect.
Ergotamine is extensively metabolized by CYP3A4. Caffeine is metabolized primarily by CYP1A2.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Ergotamine is primarily excreted in bile and feces as metabolites, with approximately 90% of a dose eliminated via the biliary-fecal route and less than 4% excreted unchanged in urine. Caffeine is extensively metabolized in the liver and its metabolites are excreted renally, with only about 1% excreted unchanged.
Approximately 90% bound to albumin.
Ergotamine is approximately 90% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein. Caffeine is about 35% bound, mainly to albumin.
1.5-2 L/kg, indicating extensive tissue distribution.
Ergotamine has a large volume of distribution, approximately 2–3 L/kg (range 1.5–4 L/kg), indicating extensive tissue distribution and binding to tissues, including the brain. Caffeine has a Vd of about 0.5–0.7 L/kg.
Oral: less than 10% due to extensive first-pass metabolism.
Oral: bioavailability of ergotamine is low and erratic due to extensive first-pass metabolism, typically <5% (range 0–5%). Sublingual: bioavailability is slightly higher but still low, around 1–3%. Rectal: bioavailability is approximately 2–5%, somewhat more consistent than oral. Caffeine is well absorbed orally with bioavailability near 100%.
Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 m L/min).
No specific dose adjustments available; contraindicated in severe renal impairment (Cr Cl < 20 m L/min) due to risk of accumulation.
Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%.
Contraindicated in hepatic impairment (Child-Pugh class B or C). Use with caution in mild impairment (Child-Pugh class A); reduce initial dose by 50% and closely monitor for adverse effects.
Not established; safety and efficacy not determined in pediatric patients.
Not recommended for patients younger than 12 years due to lack of safety and efficacy data. For adolescents aged 12-17 years: 1 mg ergotamine tartrate and 100 mg caffeine orally at onset, repeat every 30 minutes if needed; maximum 3 mg ergotamine tartrate and 300 mg caffeine per day; or rectal suppository (1 mg ergotamine tartrate/100 mg caffeine) at onset, repeat once after 1 hour; maximum 2 mg ergotamine tartrate and 200 mg caffeine per day.
Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects.
Use with caution due to increased risk of peripheral vascular disease, coronary artery disease, and reduced hepatic/renal function. Initiate at lowest effective dose (e.g., 1 mg ergotamine tartrate and 100 mg caffeine orally) and monitor for signs of ischemia. Avoid in patients over 65 with uncontrolled hypertension or vascular risk.
No FDA black box warning.
Serious or life-threatening peripheral ischemia and cerebral ischemia have been associated with ergotamine use, especially with prolonged use or overdose. Concomitant use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, protease inhibitors) increases risk.
Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism.
Risk of ergotism (ischemia, gangrene) with prolonged use or high doses,May cause vasospastic reactions, including coronary vasospasm,Overuse can lead to medication-overuse headache,Avoid concomitant use with vasoconstrictors or ergot-like drugs,May cause nausea, vomiting, and paresthesias
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
Peripheral vascular disease (e.g., Raynaud's disease),Coronary artery disease, uncontrolled hypertension,Severe renal or hepatic impairment,Sepsis or severe infection,Concurrent use of potent CYP3A4 inhibitors (e.g., macrolides, protease inhibitors),Pregnancy (teratogenic, oxytocic effects),History of hypersensitivity to ergotamine or caffeine
Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration.
Avoid grapefruit juice; it inhibits CYP3A4, increasing ergotamine absorption and risk of toxicity. Caffeine-containing foods (coffee, tea, cola) may be consumed in moderation but excessive caffeine intake may exacerbate adverse effects.
Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions.
Pregnancy Category X. Ergotamine is contraindicated in all trimesters due to potent uterotonic effects and vasoconstriction, which can cause fetal hypoxia, growth retardation, and spontaneous abortion. Caffeine may be associated with low birth weight and preterm delivery at high doses. There are no adequate studies in pregnant women.
Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding.
Contraindicated during breastfeeding. Ergotamine is excreted into breast milk and can cause ergotism (vomiting, diarrhea, convulsions) in infants. Caffeine may cause irritability and poor sleep. M/P ratio unknown.
No established safe dose in pregnancy. Avoid use. If absolutely necessary, lowest effective dose and shortest duration, but no specific pharmacokinetic data available to guide adjustments.
No dose adjustment is recommended because use is contraindicated during pregnancy. Pharmacokinetic changes (increased plasma volume, reduced binding) do not warrant adjustment in this contraindicated setting.
Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence.
Ergotamine tartrate is a serotonin 5-HT1B/1D receptor agonist and alpha-adrenergic blocker. Caffeine enhances ergotamine absorption and adds vasoconstriction. Contraindicated in coronary artery disease, uncontrolled hypertension, peripheral vascular disease, sepsis, and within 24 hours of triptans. Risk of ergotism with excessive use. Limit acute use to ≤6 mg/attack and ≤10 mg/week. Avoid prolonged daily use to prevent rebound headache.
Take exactly as prescribed; do not double doses if missed.,Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness.,Avoid smoking and caffeine as they may worsen vasoconstriction.,May cause dizziness or fainting; avoid driving until you know how the drug affects you.,Do not use with other ergot alkaloids or triptans.
Take at the first sign of migraine headache; do not use for prevention.,Do not exceed one dose per 24 hours; maximum 2 tablets per attack and 5 tablets per week.,Seek emergency care if symptoms of ergotism (cold/blue extremities, muscle pain, numbness, tingling) occur.,Avoid concurrent use with triptans or other ergot alkaloids within 24 hours.,Not for use during pregnancy or breastfeeding; use reliable contraception.,Do not consume grapefruit juice as it may increase ergotamine levels.,Report chest pain, palpitations, or severe abdominal pain immediately.
No interactions on record
"Terbutaline, a beta-2 adrenergic agonist, can cause vasodilation and increased heart rate. Ergotamine, a vasoconstrictor used for migraine, may lead to excessive vasoconstriction when combined with terbutaline due to opposing vascular effects. This interaction can result in hypertensive crisis, ischemia, or peripheral vascular complications."
"Metronidazole inhibits CYP3A4, the primary enzyme responsible for the metabolism of ergotamine. Co-administration can lead to significantly elevated ergotamine plasma concentrations, increasing the risk of ergotism—a serious condition characterized by severe vasoconstriction, ischemia, and potential gangrene of the extremities. Patients may present with symptoms such as cold, painful extremities, muscle pain, and paresthesias, requiring immediate intervention."
"Concomitant use of ergotamine and cortisone acetate is contraindicated due to the potential for severe vasospasm and ischemic events. Corticosteroids like cortisone can inhibit the metabolism of ergotamine via CYP3A4, leading to increased ergotamine concentrations. This enhances ergotamine's vasoconstrictive effects, risking digital ischemia, cerebrovascular accidents, and myocardial infarction."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERGOLOID MESYLATES vs ERGOTAMINE TARTRATE AND CAFFEINE, answered by our medical review team.
ERGOLOID MESYLATES is a Ergot Alkaloid that works by Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.. ERGOTAMINE TARTRATE AND CAFFEINE is a Ergot Alkaloid that works by Ergotamine is a partial agonist/antagonist at serotonin (5-HT), dopamine, and alpha-adrenergic receptors, causing vasoconstriction of cranial blood vessels. Caffeine enhances ergotamine absorption and has additive vasoconstrictive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERGOLOID MESYLATES and ERGOTAMINE TARTRATE AND CAFFEINE depend on the specific clinical indication. These are both Ergot Alkaloid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERGOLOID MESYLATES is: Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.. The standard adult dose of ERGOTAMINE TARTRATE AND CAFFEINE is: Oral: 2 mg ergotamine tartrate and 200 mg caffeine at onset of migraine, then 1 mg ergotamine tartrate and 100 mg caffeine every 30 minutes as needed; maximum 6 mg ergotamine tartrate and 600 mg caffeine per day or 10 mg ergotamine tartrate and 1000 mg caffeine per week. Rectal: 2 mg ergotamine tartrate and 200 mg caffeine as a single suppository at onset; repeat once after 1 hour if needed; maximum 4 mg ergotamine tartrate and 400 mg caffeine per day or 8 mg ergotamine tartrate and 800 mg caffeine per week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERGOLOID MESYLATES and ERGOTAMINE TARTRATE AND CAFFEINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERGOLOID MESYLATES is classified as Category A/B. Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. . ERGOTAMINE TARTRATE AND CAFFEINE is classified as Category D/X. Pregnancy Category X. Ergotamine is contraindicated in all trimesters due to potent uterotonic effects and vasoconstriction, which can cause fetal hypoxia, growth retardation, and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.